Skip to main content
. 2020 Dec 16;10(12):1683. doi: 10.3390/biom10121683

Figure 2.

Figure 2

Specific inhibition of GSK3 may be beneficial in acute myeloid leukemia. Left panel: The selective inhibitors BRD-0705, Tivantinib, and others reported by Neuman et al. [89] promote the differentiation of acute myeloid leukemia (AML) cells without the stabilization of β-catenin and without deleterious effects [29,43,90,91]. Right panel: The inhibition of both GSK3 paralogs leads to deleterious effects and promotes β-catenin stabilization and cell proliferation [29,85].